UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

An Alternative Development Agenda for India

Kaul, Sanjay

1, 2023

Volltextzugriff (PDF)

Dietary Intervention for Overweight and Obese Adults: Comparison of Low-Carbohydrate and Low-Fat Diets. A Meta-Analysis

PloS one, 2015-10, Vol.10 (10), p.e0139817

2015

Volltextzugriff (PDF)

The Cardiovascular Safety of Diabetes Drugs — Insights from the Rosiglitazone Experience

The New England journal of medicine, 2013-10, Vol.369 (14), p.1285-1287

2013

Volltextzugriff (PDF)

Do Women Really Respond Differently to Antiplatelet Therapies?

Journal of the American College of Cardiology, 2017-03, Vol.69 (12), p.1560-1563

Kaul, Sanjay, MD

2017

Volltextzugriff (PDF)

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death

Annals of internal medicine, 2007-10, Vol.147 (8), p.578

2007

Volltextzugriff (PDF)

Good enough: a primer on the analysis and interpretation of noninferiority trials

Annals of internal medicine, 2006-07, Vol.145 (1), p.62

2006

Volltextzugriff (PDF)

Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials

Diabetes care, 2017-07, Vol.40 (7), p.821-831

Kaul, Sanjay

2017

Volltextzugriff (PDF)

The ATLAS ACS 2–TIMI 51 Trial and the Burden of Missing Data

Journal of the American College of Cardiology, 2013-08, Vol.62 (9), p.777-781

2013

Volltextzugriff (PDF)

Choice of Optimal Anticoagulant to Support Primary PCI

Journal of the American College of Cardiology, 2015, Vol.65 (1), p.39-42

Kaul, Sanjay, MD

2015

Volltextzugriff (PDF)

Raising the Evidentiary Bar for Guideline Recommendations for TAVR: JACC Review Topic of the Week

Journal of the American College of Cardiology, 2020-08, Vol.76 (8), p.985-991

Kaul, Sanjay

2020

Volltextzugriff (PDF)

Evidence for the Universal Blood Pressure Goal of <130/80 mm Hg Is Strong: Controversies in Hypertension - Con Side of the Argument

Hypertension (Dallas, Tex. 1979), 2020-11, Vol.76 (5), p.1391-1399

Kaul, Sanjay

2020

Volltextzugriff (PDF)

Pursuit of Myocardial Ischemia for Therapeutic Decision-Making in Patients With Diabetes and Stable Ischemic Heart Disease: Reconciling Randomized Controlled Trials and Observational Studies

Diabetes care, 2022-12, Vol.45 (12), p.2823-2827

Kaul, Sanjay

2022

Volltextzugriff (PDF)

The Role of Platelet Reactivity and Genotype Testing in the Prevention of Atherothrombotic Cardiovascular Events Remains Unproven

Circulation (New York, N.Y.), 2012-03, Vol.125 (10), p.1288-1303

2012

Volltextzugriff (PDF)

Troponin Testing for Clinicians

Journal of the American College of Cardiology, 2016-11, Vol.68 (21), p.2365-2375

2016

Volltextzugriff (PDF)

Should Percutaneous Coronary Intervention Be Considered for Left Main Coronary Artery Disease?: Insights From a Bayesian Reanalysis of the EXCEL Trial

JAMA internal medicine, 2020-07, Vol.180 (7), p.1002

Kaul, Sanjay

2020

Volltextzugriff (PDF)

On the Credibility of Subgroup Analyses in the COMPLETE Trial

Journal of the American College of Cardiology, 2020-09, Vol.76 (11), p.1287-1290

Kaul, Sanjay

2020

Volltextzugriff (PDF)

Raising the Evidentiary Bar for Guideline Recommendations for TAVR

Journal of the American College of Cardiology, 2020-08, Vol.76 (8), p.985-991

Kaul, Sanjay

2020

Volltextzugriff (PDF)

Are Guidelines for Treatment of Hypertension Trustworthy?

Journal of the American College of Cardiology, 2019-06, Vol.73 (23), p.3027-3030

Kaul, Sanjay

2019

Volltextzugriff (PDF)

Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?

Circulation (New York, N.Y.), 2016-07, Vol.134 (2), p.94-96

Kaul, Sanjay

2016

Volltextzugriff (PDF)

Understanding the Merits and Drawbacks of Noninferiority Trials in Cardiovascular Medicine

Canadian journal of cardiology, 2021-09, Vol.37 (9), p.1378-1393

Kaul, Sanjay

2021

Volltextzugriff (PDF)

Impact of High Volume Energy Drink Consumption on Electrocardiographic and Blood Pressure Parameters: A Randomized Trial

Journal of the American Heart Association, 2019-06, Vol.8 (11), p.e011318

2019

Volltextzugriff (PDF)

How Strong Is the Evidence to Support Blood Pressure Treatment Goal of 130/80 mm Hg?

Circulation (New York, N.Y.), 2018-12, Vol.138 (23), p.2594-2596

Kaul, Sanjay

2018

Volltextzugriff (PDF)

The Impact of Revascularization on Mortality in Patients with Nonacute Coronary Artery Disease

The American journal of medicine, 2009-02, Vol.122 (2), p.152-161

2009

Volltextzugriff (PDF)

Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821-831

Diabetes care, 2018-03, Vol.41 (3), p.640-640

Kaul, Sanjay

2018

Volltextzugriff (PDF)

1 – 25 von 509

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(438)
Mit Volltextzugriff
(456)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(270)
Life Sciences & Biomedicine
(256)
Humans
(220)
Cardiovascular System & Cardiology
(156)
Cardiac & Cardiovascular Systems
(147)
Biological And Medical Sciences
(105)
Medical Sciences
(103)
Male
(68)
Female
(67)
Cardiology
(59)
Cardiology. Vascular System
(56)
Cardiovascular
(54)
Risk Factors
(54)
General & Internal Medicine
(53)
Medicine, General & Internal
(51)
Peripheral Vascular Disease
(49)
Internal Medicine
(39)
Treatment Outcome
(39)
Animals
(38)
Cardiovascular Disease
(37)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

An Alternative Development Agenda for India

Dietary Intervention for Overweight and Obese Adults: Comparison of Low-Carbohydrate and Low-Fat Diets. A Meta-Analysis

The Cardiovascular Safety of Diabetes Drugs — Insights from the Rosiglitazone Experience

Do Women Really Respond Differently to Antiplatelet Therapies?

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death

Good enough: a primer on the analysis and interpretation of noninferiority trials

Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials

The ATLAS ACS 2–TIMI 51 Trial and the Burden of Missing Data

Choice of Optimal Anticoagulant to Support Primary PCI

Raising the Evidentiary Bar for Guideline Recommendations for TAVR: JACC Review Topic of the Week

Evidence for the Universal Blood Pressure Goal of <130/80 mm Hg Is Strong: Controversies in Hypertension - Con Side of the Argument

Pursuit of Myocardial Ischemia for Therapeutic Decision-Making in Patients With Diabetes and Stable Ischemic Heart Disease: Reconciling Randomized Controlled Trials and Observational Studies

The Role of Platelet Reactivity and Genotype Testing in the Prevention of Atherothrombotic Cardiovascular Events Remains Unproven

Troponin Testing for Clinicians

Should Percutaneous Coronary Intervention Be Considered for Left Main Coronary Artery Disease?: Insights From a Bayesian Reanalysis of the EXCEL Trial

On the Credibility of Subgroup Analyses in the COMPLETE Trial

Raising the Evidentiary Bar for Guideline Recommendations for TAVR

Are Guidelines for Treatment of Hypertension Trustworthy?

Is the Mortality Benefit With Empagliflozin in Type 2 Diabetes Mellitus Too Good To Be True?

Understanding the Merits and Drawbacks of Noninferiority Trials in Cardiovascular Medicine

Impact of High Volume Energy Drink Consumption on Electrocardiographic and Blood Pressure Parameters: A Randomized Trial

More questions than answers after NOTION-2

How Strong Is the Evidence to Support Blood Pressure Treatment Goal of 130/80 mm Hg?

The Impact of Revascularization on Mortality in Patients with Nonacute Coronary Artery Disease

Erratum. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821-831

Suchergebnisse filtern